Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Equipment & Services  // Browsing posts in Equipment & Services

Novadaq Technologies Idea Proposal

Novadaq Technologies Idea Proposal

Research Question: Will Novadaq’s SPY Elite be widely adopted and drive the company’s growth in 2016? Report Available: Nov. 24, 2015   Blueshift’s initial research shows NVDQ’s sales momentum increasing now that its technology is transitioning into the adoption phase. But its SPY fluorescence imaging systems could still be years away from achieving angiography gold standard status, […]

Read more...

Abiomed’s Impella Will Drive Growth But Not at Projected 40%

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Companies: ABMD, STJ By: David Franklin Click here to download the report (.pdf)   Summary of Findings The Impella Platform is expected to drive growth for Abiomed Inc. (ABMD) but not at corporate’s 2020 projected sales rate of $1.2 billion to $1.8 billion, […]

Read more...

Abiomed Idea Proposal

Abiomed Idea Proposal

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Report Available: October 14, 2015   Blueshift’s initial research shows ABMD’s Impella utilization rate is increasing faster than many had expected in its Q1. ABMD, a leader in heart support technologies, then issued an aggressive five-year strategy which predicted $1.2 billion to $1.8 billion in […]

Read more...

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...

Medtronic Whisper

Medtronic Whisper

Research Question: Will Medtronic’s Covidien Solitaire, a neurovascular stent, become the new standard procedure for stroke treatments? Companies Covered: Medtronic (MDT), Stryker (SYK), Johnson and Johnson (JNJ), Boston Scientific (BSX)​ Report Available: April 17, 2015   Blueshift’s initial research shows that the Solitaire neurovascular stent is regarded as a game changer by several medical experts. […]

Read more...

Zeltiq’s CoolSculpting System and Treatment Sales Expected to Grow

Research Question: Will Zeltiq continue growing system sales and increasing procedure volume for its CoolSculpting system, or is it a fad? Companies: CUTR, ELOS, LMNS, VRX, ZLTQ By: David Franklin Click here to download the report (.pdf)   Summary of Findings Zeltiq Aesthetics Inc.’s (ZLTQ) CoolSculpting procedure is considered the industry-leading noninvasive fat reduction system. CoolSculpting system […]

Read more...

Zeltiq Aesthetics Whisper

Zeltiq Aesthetics Whisper

Research Question: Will ZLTQ continue growing system sales and increasing procedure volume for its CoolSculpting system, or is it a fad? Companies Covered: Zeltiq Aesthetics (ZLTQ), Cynosure (CYNO), Cutera (CUTR), Syneron Medical (ELOS), Lumenis (LMNS), Valeant (VRX) Report Available: February 17, 2015   Blueshift’s initial research shows ZLTQ’s CoolSculpting procedure continuing to rapidly grow in […]

Read more...

FDA Approval Gives Spectranetics a Window for Moderate Sales Growth

Research Question: Will Spectranetics’ laser atherectomy and PTA become the new standard of treatment for femoropopliteal ISR and be the catalyst for a significant revenue boost? Companies: ABT, BCR, COV, JNJ, SPNC, VOLC By: David Franklin Click here to download the report (.pdf)   Summary of Findings Spectranetics Corp. (SPNC) can expect a moderate sales increase as […]

Read more...

Although Not to Forecast Level, MDSO’s CTMS Sales Will Grow This Year

Research Question: Can Medidata capitalize on a stronger sales pipeline to reach its projected growth of 20% to 25% despite challenges from innovative competitors? Companies: IBM, MDSO, MRGE, ORCL, QCOM, PRXL By: David Franklin Click here to download the report (.pdf)   Summary of Findings As Blueshift Research found in its Dec. 13, 2013, report, Medidata Solutions Inc. […]

Read more...